Can You Take ETERNAL Blend With Tirzepatide or Semaglutide?

The medications this page covers:

Prices are all-in, covering medication, physician review, refill management and shipping, with no membership fee. GLP-1 prices are "from" prices, set by dose. Compounded medications are not FDA approved.

Tirzepatide is a single peptide that activates the GIP and GLP-1 receptors, acting on appetite, gastric emptying, and insulin and glucagon signalling (what is tirzepatide). ETERNAL is four separate peptides dissolved in one vial, each with its own literature (what is the ETERNAL blend). Three of them are the repair trio also found in GLOW; the fourth, epithalon, comes from a separate Russian line of research on pineal peptides, telomerase and circadian rhythm. By mass ETERNAL is mostly GHK-Cu: 50 of the 80 mg.

None of the four binds the GIP or GLP-1 receptor, acts on appetite, or is described as changing insulin or glucose. That makes a direct interaction with tirzepatide unlikely on mechanism. With no study of the pairing, that is the limit of what can be said.

The FDA's July 2026 review of epithalon raised continuous, long-term telomerase activation as a concern, and a 2025 cell study reported telomere extension in breast cancer cell lines. In the 2003 mouse study, overall tumour incidence was unchanged and leukaemia was less frequent, with intermittent courses. None of that is a human finding. It is why your full cancer history, and your family's, goes on the intake before either medication. More in can peptides cause cancer.

Where it fits

The case for ETERNAL alongside a GLP-1 is a separate goal: skin and connective tissue, a soft-tissue complaint from training more, or the sleep-rhythm and ageing research behind epithalon, in someone who is also on a weight program. In that case the two are doing unrelated jobs, and the question is whether your physician is comfortable adding a four-component vial to your record.

Where something else fits better

For GLP-1 stomach side effects, the live gut-health reference is plain that they are a dose and titration question for the prescribing physician, not a reason to add a second vial. ETERNAL's BPC-157 does not change that answer. See GLP-1 nausea: how to manage it.

Nausea on a GLP-1 is most likely in the days after starting and after each dose increase. Two sources of queasiness are hard to tell apart, which is the main reason to start ETERNAL when your GLP-1 dose is steady, not in the same week as an increase. Persistent nausea and vomiting, abdominal pain, yellowing of the skin or eyes, or new confusion is the pattern copper excess would produce; it is not reported at prescribed GHK-Cu doses in people with normal copper handling, but it is a same-day call. The side-effect references are tirzepatide side effects and ETERNAL blend side effects.

The ETERNAL figures are math from the vial: 0.25 mL carries a quarter of each component's per-mL concentration, and 5 mL at 0.25 mL is 20 doses. Because the proportions are fixed, every dose delivers the same split. Both run on a 28-day refill cycle, one vial per fill.

• Two vials, two syringes, two sites. Never mix ETERNAL and tirzepatide in one syringe.
• Keep your tirzepatide day fixed. On a shared weekday, inject each at a different site.
• Refrigerate both, and do not keep a multi-peptide vial past its beyond-use date.

How each product's vial is counted is in how long does a peptide vial last, and ETERNAL's units chart is in ETERNAL blend dosage.

Bloodwork is not required for any Pepti treatment. If your physician wants labs for your care, they'll ask through your account.

Semaglutide acts at GLP-1 only, where tirzepatide acts at GLP-1 and GIP, but both act through appetite and gastric emptying, carry the same boxed thyroid warning and bring the same early side effects. Nothing on this page changes for semaglutide. Semaglutide and tirzepatide are never taken together; see semaglutide vs tirzepatide.

1. Name the goal that is separate from weight, such as skin, a sore tendon from new training, or sleep rhythm.
2. List everything, including supplements, zinc, and any blend you already take, so components are not duplicated.
3. Give your full cancer history, and your family's.
4. Start when your GLP-1 dose is steady.
5. Report what happens, including nothing.

Your physician sets your directions after reviewing your intake, and every vial arrives with its directions printed on the label. More on combining is in can you take two peptides together, what peptides can you take with tirzepatide and can you take GLOW with tirzepatide. Step by step: how to get tirzepatide prescribed, and for the components GHK-Cu, BPC-157, TB-500 and epithalon.

Tirzepatide has a large human trial base in its approved form. ETERNAL has never been studied as a blend; its evidence is per component and uneven, from topical human skin studies for GHK-Cu, to early-phase human work for BPC-157, to no human trials of the TB-500 fragment, to small Russian studies that mostly used epithalon's parent extract. There is no study of ETERNAL or any component with a GLP-1.

On regulation, all four components were removed from Category 2 of the FDA's interim 503A list in April 2026. In July 2026 the FDA's advisory committee voted 8 to 6 to recommend adding BPC-157 and, by the same margin, TB-500, and 7 to 4 to recommend adding epitalon, to the 503A Bulks List; GHK-Cu is scheduled for review before the end of February 2027, and final determinations are pending. The pairing is reasonable to discuss when there is a separate reason for ETERNAL. It is not a stack shown to work better than tirzepatide alone.